- Non-diagnostic cytology (Bethesda-I) occurs in 5%-20% of thyroid nodule fine needle aspirates (FNAs), often resulting in repeat FNA procedures, inconvenience for patients, and increased healthcare costs
- Interpace Diagnostics previously presented data showing that molecular testing can provide useful diagnostic information for the majority of samples with non-diagnostic (B-I) cytology from a dedicated pass collected in RNARetain
- We hypothesized that B-I cases could potentially be addressed by molecular analysis utilizing a combination testing approach with a mutational panel (ThyGeNEXT®) along with a microRNA classifier (ThyraMIR®)
Molecular Analysis of Non-Diagnostic (B-I) Thyroid Nodule Cytology Samples Using Combined Mutational Detection and microRNA Classifier Test
ATA 2019 Chicago, IL
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
